دورية أكاديمية
Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study.
| العنوان: | Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study. |
|---|---|
| المؤلفون: | Marinho LL; Lipid Metabolism Laboratory, Instituto do Coracao (InCor) Universidade de Sao Paulo, São Paulo, Brazil., Rached FH; Department of Cardiopneumology, Instituto do Coracao (InCor) Universidade de Sao Paulo, São Paulo, Brazil., Morikawa AT; Lipid Metabolism Laboratory, Instituto do Coracao (InCor) Universidade de Sao Paulo, São Paulo, Brazil., Tavoni TM; Lipid Metabolism Laboratory, Instituto do Coracao (InCor) Universidade de Sao Paulo, São Paulo, Brazil., Cardoso APT; Department of Radiology, Instituto do Coracao (InCor) Universidade de Sao Paulo, São Paulo, Brazil., Torres RVA; Department of Radiology, Instituto do Coracao (InCor) Universidade de Sao Paulo, São Paulo, Brazil., Assuncao AN Jr; Department of Radiology, Instituto do Coracao (InCor) Universidade de Sao Paulo, São Paulo, Brazil., Serrano CV Jr; Department of Cardiopneumology, Instituto do Coracao (InCor) Universidade de Sao Paulo, São Paulo, Brazil., Nomura CH; Department of Radiology, Instituto do Coracao (InCor) Universidade de Sao Paulo, São Paulo, Brazil., Maranhão RC; Lipid Metabolism Laboratory, Instituto do Coracao (InCor) Universidade de Sao Paulo, São Paulo, Brazil. |
| المصدر: | Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2024 Feb 21; Vol. 11, pp. 1342832. Date of Electronic Publication: 2024 Feb 21 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101653388 Publication Model: eCollection Cited Medium: Print ISSN: 2297-055X (Print) Linking ISSN: 2297055X NLM ISO Abbreviation: Front Cardiovasc Med Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media S.A., [2014]- |
| مستخلص: | Introduction: Studies in cholesterol-fed rabbits showed that anti-proliferative chemotherapeutic agents such as paclitaxel associated with solid lipid nanoparticles (LDE) have marked anti-atherosclerotic effects. In addition, association with LDE nearly abolishes paclitaxel toxicity. We investigated whether treatment with LDE-paclitaxel changes plaque progression by coronary CT angiography and is safe in patients with chronic coronary artery disease. Methods: We conducted a prospective, randomized, double-blind, placebo-controlled pilot study in patients with multi-vessel chronic coronary artery disease. Patients were randomized to receive IV infusions of LDE-paclitaxel (paclitaxel dose: 175 mg/m 2 body surface) or LDE alone (placebo group), administered every 3 weeks for 18 weeks. All participants received guideline-directed medical therapy. Clinical and laboratory safety evaluations were made at baseline and every 3 weeks until the end of the study. Analysis of inflammatory biomarkers and coronary CTA was also performed at baseline and 4 weeks after treatment. Results: Forty patients aged 65.6 ± 8 years, 20 in LDE-paclitaxel and 20 in placebo group were enrolled. Among those, 58% had diabetes, 50% had myocardial infarction, and 91% were in use of statin and aspirin. Baseline demographics, risk factors, and laboratory results were not different between groups. In all patients, no clinical or laboratory toxicities were observed. From the baseline to the end of follow-up, there was a non-significant trend toward a decrease in IL-6 levels and hsCRP in the LDE-paclitaxel group (-16% and -28%, respectively), not observed in placebo. Regarding plaque progression analysis, variation in plaque parameter values was wide, and no difference between groups was observed. Conclusion: In patients with multivessel chronic coronary artery disease and optimized medical therapy, LDE-paclitaxel was safe and showed clues of potential benefits in reducing inflammatory biomarkers. Clinical Trial Registration: https://clinicaltrials.gov/study/NCT04148833, identifier (NCT04148833). Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2024 Marinho, Rached, Morikawa, Tavoni, Cardoso, Torres, Assuncao, Serrano, Nomura and Maranhão.) |
| References: | Lancet. 2018 Nov 10;392(10159):1736-1788. (PMID: 30496103) Eur Heart J. 2014 Jul 14;35(27):1782-91. (PMID: 24864079) Expert Opin Drug Deliv. 2017 Oct;14(10):1217-1226. (PMID: 28042707) JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 2):305-316. (PMID: 29055633) Expert Opin Drug Deliv. 2015 Jul;12(7):1135-47. (PMID: 25585820) Eur J Med Chem. 2019 Jun 1;171:310-331. (PMID: 30953881) Lancet. 2023 Apr 15;401(10384):1293-1301. (PMID: 36893777) Clinics (Sao Paulo). 2016 Aug;71(8):435-9. (PMID: 27626473) Vasc Med. 2019 Oct;24(5):414-421. (PMID: 31277561) Nat Rev Immunol. 2006 Jul;6(7):508-19. (PMID: 16778830) JACC Cardiovasc Imaging. 2018 Oct;11(10):1475-1484. (PMID: 29909109) Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1222-1227. (PMID: 28428221) Clin Cardiol. 2017 Apr;40(4):210-215. (PMID: 27883201) Circ Res. 2016 Jan 8;118(1):145-56. (PMID: 26837745) Int J Cardiovasc Imaging. 2013 Jun;29(5):1177-90. (PMID: 23417447) JACC Cardiovasc Imaging. 2010 Jul;3(7):691-8. (PMID: 20633846) Am Heart J. 2016 Oct;180:29-38. (PMID: 27659880) Expert Opin Emerg Drugs. 2017 Mar;22(1):1-26. (PMID: 27927063) Circ Res. 2021 May 28;128(11):1728-1746. (PMID: 33998272) N Engl J Med. 1995 Apr 13;332(15):1004-14. (PMID: 7885406) Atherosclerosis. 2008 Apr;197(2):959-66. (PMID: 18289548) Nature. 2011 May 19;473(7347):317-25. (PMID: 21593864) JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S28-37. (PMID: 22421228) Clin Chem. 2009 Feb;55(2):209-15. (PMID: 19095723) Eur J Haematol. 2017 Jun;98(6):529-541. (PMID: 28208215) J Cardiovasc Comput Tomogr. 2009 Mar-Apr;3(2):122-36. (PMID: 19272853) Circulation. 2020 May 5;141(18):1452-1462. (PMID: 32174130) Arq Bras Cardiol. 2020 Aug 28;115(2):152-160. (PMID: 32696855) Gynecol Oncol. 2005 Apr;97(1):178-82. (PMID: 15790455) Atherosclerosis. 2016 Dec;255:73-79. (PMID: 27835741) Eur Heart J. 2014 Mar;35(9):578-89. (PMID: 24026779) |
| فهرسة مساهمة: | Keywords: atherosclerosis; coronary artery disease; drug-Related side effects and adverse reactions; inflammation; interleukin-6; nanoparticles; paclitaxel |
| سلسلة جزيئية: | ClinicalTrials.gov NCT04148833 |
| تواريخ الأحداث: | Date Created: 20240307 Latest Revision: 20240308 |
| رمز التحديث: | 20240308 |
| مُعرف محوري في PubMed: | PMC10915057 |
| DOI: | 10.3389/fcvm.2024.1342832 |
| PMID: | 38450375 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2297-055X |
|---|---|
| DOI: | 10.3389/fcvm.2024.1342832 |